Literature DB >> 22154015

Development of a fast ELISA for quantifying polio D-antigen in in-process samples.

R ten Have1, Y E Thomassen, M R J Hamzink, W A M Bakker, O E M Nijst, G Kersten, G Zomer.   

Abstract

A fast ELISA was developed and qualified for analysis of polio D-antigen. The original 20 h-protocol was optimized by minimizing the total incubation time to 1 h, and by replacing the signal reagent 3,3',5,5'-tetramethylbenzidine by a chemiluminogenic signal reagent with a theoretical low intrinsic background and high dynamic range.
Copyright © 2011 The International Alliance for Biological Standardization. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22154015     DOI： 10.1016/j.biologicals.2011.11.004

Source DB:  PubMed          Journal:  Biologicals        ISSN： 1045-1056            Impact factor:   1.856


  6 in total

1.  Hematopoietic cancer cell lines can support replication of Sabin poliovirus type 1.

Authors:  Dinja Oosterhoff; Gerard van de Weerd; Gerco van Eikenhorst; Tanja D de Gruijl; Leo A van der Pol; Wilfried A M Bakker
Journal:  Biomed Res Int       Date:  2015-02-28       Impact factor: 3.411

2.  Development of thermostable lyophilized inactivated polio vaccine.

Authors:  Heleen Kraan; Paul van Herpen; Gideon Kersten; Jean-Pierre Amorij
Journal:  Pharm Res       Date:  2014-04-24       Impact factor: 4.200

3.  Incompatibility of lyophilized inactivated polio vaccine with liquid pentavalent whole-cell-pertussis-containing vaccine.

Authors:  Heleen Kraan; Rimko Ten Have; Larissa van der Maas; Gideon Kersten; Jean-Pierre Amorij
Journal:  Vaccine       Date:  2016-07-26       Impact factor: 3.641

4.  Development of an animal component free production process for Sabin inactivated polio vaccine.

Authors:  Diego A Suarez-Zuluaga; Leo A van der Pol; Aart G van 't Oever; Wilfried A M Bakker; Yvonne E Thomassen
Journal:  Vaccine X       Date:  2022-09-30

5.  Next generation inactivated polio vaccine manufacturing to support post polio-eradication biosafety goals.

Authors:  Yvonne E Thomassen; Aart G van 't Oever; Monique G C T van Oijen; René H Wijffels; Leo A van der Pol; Wilfried A M Bakker
Journal:  PLoS One       Date:  2013-12-12       Impact factor: 3.240

6.  Improved poliovirus D-antigen yields by application of different Vero cell cultivation methods.

Authors:  Yvonne E Thomassen; Olaf Rubingh; René H Wijffels; Leo A van der Pol; Wilfried A M Bakker
Journal:  Vaccine       Date:  2014-02-26       Impact factor: 3.641
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.